Survival in Men Treated for Lung Cancer: A Single-Center Retrospective Cohort Study in Poland
Open Access
- 7 April 2026
- journal article
- research article
- Published by MDPI AG in Healthcare
- Vol. 14 (7) , 970
Abstract
Introduction: Lung cancer remains the leading cause of cancer-related mortality among men in Poland. Prognosis is generally poor, largely due to late diagnosis at advanced stages and the aggressive biological nature of the disease. Aim: This study aimed to evaluate the effectiveness of various treatment modalities and determine their impact on overall survival in male patients diagnosed with small-cell (SCLC) and non-small-cell lung cancer (NSCLC). Methods: This retrospective cohort study analyzed 1431 men (mean age: 61.5 years) treated at the Katowice Oncology Center in Poland between 2002 and 2012. Overall survival was assessed using the Kaplan–Meier method and multivariable Cox proportional hazards regression. Evaluated prognostic factors included clinical stage, surgical intervention (partial or total lung resection), first-line treatment regimen, and the number of treatment cycles. Results: Survival probabilities declined progressively with advancing clinical stage for both SCLC and NSCLC. Patients who underwent surgical resection demonstrated significantly longer survival compared to non-surgically treated patients (p < 0.001). Furthermore, combined radiochemotherapy yielded superior therapeutic outcomes compared to chemotherapy alone. In the non-surgical NSCLC cohort, first-line treatment with platinum derivatives combined with gemcitabine resulted in the highest 1-year survival rate compared to other pharmacological schemes. Discussion: The high mortality observed within the first 12 months post diagnosis reflects the late-stage presentation common during the study period. The findings align with established oncological principles, confirming that surgical resection and multimodal therapies offer the greatest survival advantages for eligible patients. Conclusions: Survival rates for both SCLC and NSCLC are overwhelmingly dictated by early diagnosis and the feasibility of surgical resection. Improving long-term outcomes depends heavily on implementing effective lung cancer screening programs to detect the disease at operable stages and utilizing optimized combined treatment protocols.Keywords
Funding Information
- Medical University of Silesia (BNW-1-162/N/5/I)
- Medical University of Silesia (BNW-1-172/N/4/O)
This publication has 60 references indexed in Scilit:
- ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvalsCurrent Problems in Cancer, 2024
- Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and DevelopmentsDrugs, 2024
- Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancerCochrane Database of Systematic Reviews, 2020
- Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non–Small-Cell Lung CancerJAMA Oncology, 2017
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studiesInternational Journal of Surgery, 2014
- Benefits and Harms of CT Screening for Lung CancerJAMA, 2012
- Screening by Chest Radiograph and Lung Cancer MortalityJAMA, 2011
- Lobectomy leads to optimal survival in early-stage small cell lung cancer: A retrospective analysisThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry studyLung Cancer, 2005
- Small cell lung cancer in Norway. Should more patients have been offered surgical therapy?European Journal of Cardio-Thoracic Surgery, 2004